Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended) A compound having the Formula I:



I

or a pharmaceutically acceptable salt, or solvate thereof, wherein:

n is ~~an integer from 1 to 2~~ 2;

R_1 is selected from the group consisting of:

(i)



where Y is alkylene, and

R_3 and R_4 are the same or different and are selected from hydrogen, alkyl, ~~or~~ aryl, or arylalkyl, or R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms optionally interrupted by a nitrogen or oxygen;

(ii) pyridylalkyl; and

(iii) piperidin-4-yl, optionally substituted by alkyl, aryl or aralkyl;

and

R_2 is selected from the group consisting of:

(i) optionally substituted phenoxyphenyl;

(ii) optionally substituted phenylthiophenyl;

(iii) optionally substituted benzyloxyphenyl;

(iv) optionally substituted benzylthiophenyl;

(v)



wherein R_6 and R_7 are independently hydrogen or alkyl; and p and q are integers from 0 to 4;

(vi)



wherein R_8 is hydrogen, halogen or alkyl;

(vii)



wherein R_9 is hydrogen or alkyl; and

(viii) naphthalenyl.

2. (original) The compound according to claim 1, wherein R_1 is



and Y is ethylene or propylene.

3. (currently amended) The compound according to claim 1, wherein R_1 is

(i)



where R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms;

Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain; and

R_2 is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

4. (currently amended) The compound according to claim 3, wherein R_3 and R_4 together form an alkylene chain of 5 carbon atoms; and Y is ~~an optionally substituted~~ a C_{2-4} alkylene chain.

5. (currently amended) The compound according to claim 3, wherein R_3 and R_4 together form an alkylene chain of 4 carbon atoms, and Y is ~~an optionally substituted~~ a C_{2-4} alkylene chain.

6. (currently amended) The compound according to claim 1, wherein R_1 is



where R_3 and R_4 are independently hydrogen, alkyl or ~~alkylenylarylarylalkyl~~, Y is ~~an optionally substituted~~ a C_{1-4} alkylene chain; and

R_2 is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

7. (original) The compound according to claim 1, wherein R_1 is pyridyl(C_{1-4})alkyl.

8. (original) The compound according to claim 7, wherein R_2 is phenoxyphenyl or benzyloxyphenyl, wherein the phenoxy moiety is optionally substituted with alkyl, halogen or haloalkyl.

9. (original) The compound of claim 8, wherein R_1 is pyridylmethyl, pyridylethyl or pyridylpropyl.

10. (original) The compound according to claim 1, wherein R_1 is an optionally substituted piperidin-4-yl.

11. (original) The compound according to claim 10, wherein R_1 is 1-benzylpiperidin-4-yl.

12. (original) The compound according to claim 1, wherein R_2 is



13. (currently amended) The compound according to claim 12, wherein R_1 is



where R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms;

Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

14. (currently amended) The compound according to claim 12, wherein R_1 is



where R_3 and R_4 are independently hydrogen, alkyl or ~~alkylenylaryl~~arylalkyl, and Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

15. (currently amended) The compound of claims 13 ~~or 14~~, wherein $p = 0$.

16. (currently amended) The compound according to claim 1, wherein R_2 is



17. (currently amended) The compounds according to claim 16, wherein R_1 is



where R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms;

Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

18. (currently amended) The compound according to claim 16, wherein R_1 is



where R_3 and R_4 are independently hydrogen, alkyl or ~~alkylenylaryl~~arylalkyl, and Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

19. (original) The compound according to claim 16, wherein R_8 is hydrogen.

20. (original) The compound according to claim 1, wherein R_2 is



21. (currently amended) The compound according to claim 20, wherein R_1 is



where R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms;

Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

22. (currently amended) The compound according to claim 20, wherein R_1 is



where R_3 and R_4 are independently hydrogen, alkyl or ~~alkylenylaryl~~arylalkyl, and Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

23. (original) The compound according to claim 1, wherein R_2 is naphthalene.

24. (currently amended) The compound according to claim 23, wherein R_1 is



where R_3 and R_4 together form an alkylene chain having 4 to 5 carbon atoms;

Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

25. (currently amended) The compound according to claim 23, wherein R_1 is



where R_3 and R_4 are independently hydrogen, alkyl or ~~alkylenylaryl~~arylalkyl, and Y is ~~an optionally substituted~~ a C_{1-6} alkylene chain.

26. (cancelled)

27. (original) A pharmaceutical composition, comprising the compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

28. (original) A method of making a compound according to claim 1 wherein said method comprises reacting:

(i) an amine having the Formula II:

 *II*

and

(ii) an aldehyde having the Formula III:



III

in the presence of a mercapto acid having the Formula IV:



IV

wherein R_1, R_2 and *n* are as defined in claim 1.

29. (original) The method according to claim 28, wherein the reaction is conducted in the presence of toluene.

30. (original) The method according to claim 28, wherein the reaction is conducted in the presence of at least one 4 Angstrom molecular sieve.

31. (original) The method according to claim 28, wherein the reaction is conducted at a temperature of from about 50°C to about 110°C.

32. (original) The method according to claim 28, wherein the reaction is conducted for about 2 hours to about 24 hours.

33. (original) A method of treating, preventing or ameliorating a disorder responsive to blockage of sodium channels in a mammal suffering therefrom, comprising

administering to a mammal in need of such treatment an effective amount of a compound according to claim 1, or pharmaceutically acceptable salt thereof.

34. (original) The method according to claim 33, wherein said disorder is selected from the group consisting of: neuronal damage; a neurodegenerative condition, acute or chronic pain, depression, and diabetic neuropathy.

35. (original) The method according to claim 33, wherein said neuronal damage is caused by focal or global ischemia.

36. (original) The method according to claim 33, wherein said neurodegenerative condition is amyotrophic lateral sclerosis (ALS).

37. (original) The method according to claim 33 wherein said mammal is a human, dog or cat.

38. (original) A pharmaceutical composition for treatment of a mammal having a disorder or condition responsive to blockage of sodium channels, which comprises an amount of the compound according to claim 1, or a pharmaceutically effective salt thereof, that is effective for treating said disorder or condition, and a pharmaceutically acceptable carrier.

39. (cancelled)

40. (new) The compound according to claim 1, wherein said compound is selected from the group consisting of:

3-(2-piperidinylethyl)-2-(2,2-diphenylethenyl) thiazinidin-4-one; and

3-(*N*,*N*-dimethylethylamino)-2-(2,2-diphenylethenyl) thiazinidin-4-one.